InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – Nasdaq

InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – Nasdaq

InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – Nasdaq
Published on 2018-12-19